Literature DB >> 7500022

Metalloproteinase-mediated release of human Fas ligand.

N Kayagaki1, A Kawasaki, T Ebata, H Ohmoto, S Ikeda, S Inoue, K Yoshino, K Okumura, H Yagita.   

Abstract

Fas ligand (FasL) is a type II integral membrane protein homologous with tumor necrosis factor (TNF). Recent studies indicate that TNF is processed to yield the soluble cytokine by metalloproteinases at the cell surface of activated macrophages and T cells. In the present study, we investigated whether FasL is also released by metalloproteinases. Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies. This surface accumulation of mFasL was associated with the decrease of soluble FasL (p27) in the supernatant as estimated by quantitative ELISA and immunoprecipitation with anti-human FasL monoclonal antibodies. These results indicate that human FasL is efficiently released from the cell surface by metalloproteinases like TNF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500022      PMCID: PMC2192231          DOI: 10.1084/jem.182.6.1777

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

Review 1.  Fas and Fas ligand: a death factor and its receptor.

Authors:  S Nagata
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

Review 2.  The role of APO-1-mediated apoptosis in the immune system.

Authors:  P H Krammer; J Dhein; H Walczak; I Behrmann; S Mariani; B Matiba; M Fath; P T Daniel; E Knipping; M O Westendorp
Journal:  Immunol Rev       Date:  1994-12       Impact factor: 12.988

Review 3.  Fas-mediated cytotoxicity--a new immunoregulatory and pathogenic function of Th1 CD4+ T cells.

Authors:  H Yagita; S Hanabuchi; Y Asano; T Tamura; H Nariuchi; K Okumura
Journal:  Immunol Rev       Date:  1995-08       Impact factor: 12.988

4.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

5.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

6.  Human Fas ligand: gene structure, chromosomal location and species specificity.

Authors:  T Takahashi; M Tanaka; J Inazawa; T Abe; T Suda; S Nagata
Journal:  Int Immunol       Date:  1994-10       Impact factor: 4.823

Review 7.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

8.  Human T lymphocytes express a member of the Matrix Metalloproteinase gene family.

Authors:  W Conca; F Willmroth
Journal:  Arthritis Rheum       Date:  1994-06

9.  Fas-mediated cytotoxicity by freshly isolated natural killer cells.

Authors:  H Arase; N Arase; T Saito
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes.

Authors:  P D Crowe; B N Walter; K M Mohler; C Otten-Evans; R A Black; C F Ware
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  157 in total

1.  Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease.

Authors:  A Di Sabatino; R Ciccocioppo; S D'Alò; R Parroni; D Millimaggi; M G Cifone; G R Corazza
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

2.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  Apoptosis in rat spontaneous chronic pancreatis: role of the Fas and Fas ligand system.

Authors:  S B Su; Y Motoo; M J Xie; N Sawabu
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

4.  CD95 ligand expression as a mechanism of immune escape in breast cancer.

Authors:  M Müschen; C Moers; U Warskulat; J Even; D Niederacher; M W Beckmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 5.  Peripheral biomarkers of endometriosis: a systematic review.

Authors:  K E May; S A Conduit-Hulbert; J Villar; S Kirtley; S H Kennedy; C M Becker
Journal:  Hum Reprod Update       Date:  2010-05-12       Impact factor: 15.610

6.  Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.

Authors:  I Herr; D Wilhelm; T Böhler; P Angel; K M Debatin
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

7.  Serum levels of soluble Fas ligand in patients with silicosis.

Authors:  A Tomokuni; T Otsuki; Y Isozaki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

8.  Lack of activation induced cell death in human T blasts despite CD95L up-regulation: protection from apoptosis by MEK signalling.

Authors:  L S Walker; J D McLeod; G Boulougouris; Y I Patel; C N Ellwood; N D Hall; D M Sansom
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

9.  Reduced apoptosis and increased inflammatory cytokines in granulomas caused by tuberculous compared to non-tuberculous mycobacteria: role of MPT64 antigen in apoptosis and immune response.

Authors:  T Mustafa; H G Wiker; O Mørkve; L Sviland
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

10.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.